1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop repot Updated 2008. www. goldcopd.com Last accessed: June 2008.
2. Хроническая обструктивная болезнь легких. Под ред. А.Г.Чучалина. М.: Атмосфера, 2008.
3. Celli B, ZuWallack R, Wang S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743–8.
4. O'Donnell DE, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832–40.
5. Tashkin DP, Celli B, Senn S et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med 2008; 359: 1543–54.
6. Troosters T, Kesten S, Burkhart D et al. Effectiveness of Tiotropium as First Maintenance Drug in Patients with COPD. Secondary Analysis of the UPLIFT Trial. Am J Respir Crit Care Med 2009; 179: A2467.
7. Littner MR, Llovite JS, Tashkin DP et al. Long-acting bronchodilatation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1136–42.
8. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009; 34 (1): 13–6.
9. Hubbard RB, Smith CJ, Smeeth L et al. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002; 166: 1563–6.
10. .Suissa S, Baltzan M, Kremer R et al. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004; 169: 83–8.
11. .Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998; 280: 539–43.
12. Ernst P, Baltzan M, Deschenes J et al. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006; 27: 1168–74.
13. Gan WQ, Man SF, Sin DD. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med 2005; 5: 3–10.
14. Hattotuwa KL, Gizycki MJ, Ansari TW et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165: 1592–6.
15. Bourbeau J, Christodoulopoulos P, Maltais F et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007; 62: 938–43.
16. Ito K, Ito M, Elliott WM et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967–76.
17. Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Ann Rev Physiol 2008; [Epub Ahead of Print PMD: 18817512].
18. Sin DD, Man SFP, Marciniuk DD et al.; for the ABC (Advair, Biomarkers in COPD) Investigators. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 1207–14.
19. Hartl D, Griese M. Surfactant protein D in human lung diseases. Eur J Clin Invest 2006; 36: 423–35.
20. Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74–81.
21. Calverley PM, Anderson JA, Celli B et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 22: 356 (8): 775–89.